CYP19A1 and breast carcinoma: Aromatase, in particular, is a key enzyme in estrogen synthesis, primarily catalyzing the aromatization of androstenedione and testosterone to estrogens, and serves as an important therapeutic target for endocrine therapy using aromatase inhibitors (AI) in breast cancer patients [15].